STADA Arzneimittel AG (STADA) is a Germany-based company active in the pharmaceutical sector, concentrating on the development and marketing of products with off-patent active pharmaceutical ingredients. The Company’s primary business segments are: Generics, comprised of low-priced and active-ingredient products, and Branded Products, focusing on multisource products that are accessible without active ingredient research. STADA’s generic drugs are marketed by the Group subsidiary, STADApharm GmbH, through a sales network including Austria, Belgium, Bosnia, Portugal and the United Kingdom. Its branded products are distributed internationally as well, in such countries as Bulgaria, the Czech Republic, Denmark, Russia, Thailand and Vietnam. The Company operates through subsidiaries located in Germany, Switzerland, Russia, Macedonia, Serbia, Montenegro, Bulgaria, Romania and Poland, as well as in the United States.

AlphaRx, Inc., a pharmaceutical company, engages in the research and development of therapeutic products in Canada. The company is developing novel formulations of existing drugs that are insoluble or poorly soluble in water, utilizing its proprietary Bioadhesive Colloidal Dispersion drug delivery systems. Its principal products include Indaflex, a topical cream for the treatment of osteoarthritis of the knee; and Zysolin, an inhaled Tobramycin nanoparticles intended for the adjunctive treatment of Pseudomonas aeruginosa pneumonia in intubated and mechanically-ventilated patients. Indaflex completed a Phase II Proof of Concept clinical trial and Zysolin is in pre clinical stage. The company was formerly known as Logic Tech International, Inc. and changed its name to AlphaRx, Inc. in January 2000. AlphaRx, Inc. was founded in 1997 and is based in Markham, Canada.

GlaxoSmithKline plc company was founded in 1935 and is based in Brentford, the United Kingdom. GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, over the counter (OTC) medicines, and health related consumer products. The company offers prescription medicines to treat a range of conditions, such as infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer. It also markets approximately 25 vaccines to prevent life-threatening or crippling illnesses, such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza, and bacterial meningitis. In addition, the company offers OTC medicines, such as alli, a weight loss medicine; Panadol, a paracetamol/acetaminophen analgesic; smoking control products under the NicoDerm, NiQuitin CQ, Nicabate, and Nicorette names; and other brands, including Breathe Right nasal strips and Tums. Its oral healthcare products primarily comprise Aquafresh, a range of toothpastes, toothbrushes, and mouthwashes; Sensodyne, a range of toothpastes and toothbrushes, including Pronamel to protect from acid erosion; Biotene, a treatment for dry mouth; and Polident, PoliGrip, and Corega, which are denture care cleansers and adhesives. Further, the company provides nutritional healthcare products, such as Lucozade, a range of energy and sports drinks; Horlicks, a range of milk-based malted food and chocolate drinks; and Ribena, a blackcurrant juice-based drink. GlaxoSmithKline operates in Europe, North America, Central and South America, the Caribbean, Asia, Australia, the Middle East, Africa, and the Southeast Asia.

Antisoma plc company was founded in 1988. Antisoma is anti-cancer. The drug development firm scouts academic or cancer research institutions for promising new oncology drug candidates and snaps them up. Once the drugs are in its pipeline, Antisoma conducts preclinical and clinical trials. The company's leading candidates in clinical trials include possible treatments for lung cancer, acute myeloid leukemia, and breast cancer. Its 2008 acquisition of Xanthus Pharmaceuticals brought along more candidates, and helped Antisoma expand in the US. Antisoma also partners with larger drug makers and research groups, including Novartis, to develop and commercialize products.

Bluebonnet, which manufactures the majority of its products at its facility in Texas, was founded in 1991. Bluebonnet Nutrition Corp. makes and markets vitamins and other dietary supplements, including amino acids and herbs, under the Bluebonnet brand name. It provides its supplements in multiple forms, such as capsules, soft gels, powders, and liquids. Lead products include Super Earth Phytonutrient Soy Protein Powder and Multi-Action Whey of Life Protein Powder. The family-owned company sells its products in health and natural food stores throughout the US, as well as in Europe and Asia, to retailers that include Whole Foods Market.

AERES Biomedical Ltd. company was founded in 1999. AERES Biomedical develops therapeutic antibodies. The biopharmaceutical research company has developed more than 20 antibody candidates though collaborative partnerships with other biotech and pharmaceutical companies, many of which are in clinical trial stages. ABC-48 (an antibody for the treatment of deep vein thrombosis) and ABC-120 (an antibody for treating malaria) are two of the company's top candiates. AERES' products target debilitating and life-threatening illnesses, such as infectious, inflamatory, and cardiovascular diseases.

PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma, Inc. engages in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The company licenses its technologies to make and sell antibodies that bind to respiratory syncytial virus, as well as antibodies that bind to the alpha subunit of the VLA-4 integrin. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006.

OXiGENE, Inc. company was founded in 1988 and is headquartered in Waltham, Massachusetts. OXiGENE, Inc., a biopharmaceutical company, develops small-molecule therapeutics to treat cancer and eye diseases in the United States. It focuses on the development and commercialization of drug candidates that disrupt abnormal blood vessels associated with solid tumor progression and visual impairment in ocular diseases. The company's product ZYBRESTAT, which is in Phase II/III pivotal registration study as a potential treatment for anaplastic thyroid cancer, as well as in Phase II clinical trials for other solid tumors, including non-small cell lung cancer and platinum resistant ovarian cancer. It also develops a topical formulation of ZYBRESTAT for ophthalmological diseases and conditions, such as age-related macular degeneration. In addition, OXiGENE develops OXi4503, which is in Phase I clinical trial for solid tumors. It has a strategic collaboration agreement with Symphony Capital Partners, L.P. to support the advancement of ZYBRESTAT for oncology and ophthalmology.

Trimeris, Inc. was founded in 1993 and is based in Durham, North Carolina. Trimeris, Inc., a biopharmaceutical company, engages primarily in the commercialization of a class of fusion inhibitors for antiviral drug treatments. Its fusion inhibitors impair viral fusion, a complex process by which viruses attach to, penetrate, and infect host cells. The company offers FUZEON, a human immunodeficiency virus (HIV) fusion inhibitor and a 36-amino acid synthetic peptide that binds to a key region of an HIV surface protein called gp41 under a collaboration with F. Hoffmann-La Roche Ltd. Its FUZEON inhibitor blocks HIV viral fusion by interfering with certain structural rearrangements within gp41 that are required for HIV to fuse to and enter a host cell. FUZEON is approved in the United States, Canada, and the European Union. The company also holds TRI-1144, a next generation fusion inhibitor candidate that completed Phase I clinical trials.

Instrumentation Laboratory Company develops and manufactures diagnostic medical equipment primarily for hospitals and clinical laboratories around the globe. The company provides critical care systems, hemostasis products, and information management services. Its product lines include GEM and Synthesis analyzers for critical care diagnostics, and ACL and HemosIL analyzers and reagents for automated clot-timing testing. Its products are marketed through global affiliates and third-party distributors. Instrumentation Laboratory was established in 1959 and is a division of private Spanish health care company Werfen Group.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.